Medicare Permits Separate Vaccine Billing For Product, Administration
Executive Summary
CMS will allow Part D vaccine administration to be billed and reimbursed separately from product costs in 2008, the agency states in guidance to Medicare drug plan sponsors issued May 14
You may also be interested in...
Medicare Payment Cuts For Vaccines: MedPac Suggests Moving To New WAC-Reimbursement Formula
Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.
COVID And Medicare: Pricing Restraints Needed For Part B Vaccines, MedPAC Panelists Say
GSK’s blockbuster Shingrix and other Part D vaccines would be switched to Part B under proposal being developed by influential advisory commission. Lack of pricing controls in Part B is generating concerns among panelists, though, as MedPAC aims to finalize its recommendations on revising Medicare reimbursement for vaccines by next spring.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.